ArticlePhytotherapy research : PTR2026
Curcumol Inhibits the Invasion and Migration of Breast Cancer via miR-206/NCL/ERα36.
Article in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Breast cancer (BC) is a highly heterogeneous and aggressive disease with high mortality. Curcumol, a major bioactive component from Curcumae kwangsiensis, has shown antitumor activity by targeting nucleolin (NCL) and its interaction with ERα36. NCL is an RNA-binding protein that interacts with miR-206, a tumor-suppressive miRNA that inhibits EMT and invasion by regulating target gene expression. However, whether curcumol's effect on BC invasion and migration, as well as the NCL/ERα36 interaction, is regulated by miR-206 remains unclear. Cell migration and invasion were assessed using wound healing and transwell assays. Dual-luciferase reporter and RIP assays were performed to confirm NCL as a direct target of miR-206. Western blotting and qRT-PCR were used to evaluate protein and miRNA expression. Animal experiments were conducted to explore the inhibitory effect of curcumol on invasion and migration in vivo. Curcumol significantly inhibited the invasion and migration of breast cancer cells, while potentiating the inhibitory effects of NCL knockdown on these processes. NCL was identified as a downstream target of miR-206, and curcumol inhibits the invasion and migration of breast cancer cells via downregulating NCL expression and is associated with increased miR-206 levels. Moreover, curcumol inhibits the invasion and migration of breast cancer cells by downregulating the NCL/ERα36 interaction. The anti-breast cancer effect of curcumol is related to its regulation of the expression of miR-206 and NCL and inhibits the invasion and migration of breast cancer via the miR-206/NCL/ERα36 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.